8 апреля 2020  |  
5:59 PM  February 25, 2020

TSU with colleagues create effective drug for influenza treatment

© РИА Томск. Яков АндреевTSU with colleagues create effective drug for influenza treatment

TOMSK, Feb 25 – RIA Tomsk. Scientists of Tomsk State University (TSU) together with colleagues from other Siberian research centers developed a new drug for influenza treatment and prevention; preclinical studies have shown that antiviral activity of the drug is almost two times higher than the well-known foreign counterpart, the university’s press service said on Tuesday.

It is specified that the project was implemented within the framework of the federal target program "Pharma 2020". It is attended by employees of TSU, Institute for Problems of Chemical and Energetic Technologies of the Siberian Branch of the RAS (IPCET SB RAS, Biysk), and Goldberg Research Institute of Pharmacology and Regenerative Medicine Clinic of Tomsk National Research Medical Center (Tomsk NRMC). The industrial partner of the project is scientific and production centre Chemical Technologies (SPC ChT).

"Most pharmaceutical substances are manufactured in China. It is important for Russia to change this proportion by creating domestic drugs that are not inferior to foreign ones in efficiency. One of these drugs appeared as a result of the joint work of TSU, two academic institutes and SPC ChT", – the vice-rector of TSU for scientific and innovative activities Alexander Vorozhtsov is quoted.

© РИА Томск. Павел Стефанский
It is specified that scientists have developed a new technology for the synthesis of the pharmaceutical substance of oseltamivir ethoxy succinas and received a drug with a double antiviral effect. According to the developers, the innovative oseltamivir may appear on the market by 2025.

"There is already a finished dosage form. A patent has been received for the drug. The results of preclinical studies showed that the new drug has improved characteristics. Its antiviral activity was almost two times higher than that of the famous Swiss drug Tamiflu, which is widely used for influenza treatment", – is said in the report.

According to the university, studies conducted by Siberian pharmacologists have shown that the new drug is characterized by low general and chronic toxicity, does not have a mutagenic, carcinogenic and allergenic effect. It is expected that the production of the drug and its final cost to the consumer will be significantly lower than the cost of the foreign counterpart.

Сайт РИА Томск /riatomsk.ru/ содержит информацию, подготовленную Региональным информационным агентством "Томск" (РИА Томск) с территорией распространения – Российская Федерация, зарубежные страны.
РИА Томск зарегистрировано в Федеральной службе по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор) 06 ноября 2019 г. Свидетельство о регистрации ИА № ФС 77-77122.
Настоящий ресурс может содержать материалы 18+. Материалы, размещенные на правах рекламы, выходят под знаком "реклама". РИА Томск не несет ответственности за партнерские материалы.
Главные новости дня в нашей рассылке